Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) and Petros Pharmaceuticals (NASDAQ:PTPI – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.
Risk and Volatility
Protagonist Therapeutics has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Protagonist Therapeutics and Petros Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Protagonist Therapeutics | 0 | 0 | 6 | 1 | 3.14 |
| Petros Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
Insider & Institutional Ownership
98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 5.4% of Protagonist Therapeutics shares are held by insiders. Comparatively, 36.4% of Petros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Protagonist Therapeutics and Petros Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Protagonist Therapeutics | $319.12 million | 8.69 | -$78.96 million | $2.44 | 19.37 |
| Petros Pharmaceuticals | $4.12 million | 0.69 | -$8.16 million | ($7.37) | -0.06 |
Petros Pharmaceuticals has lower revenue, but higher earnings than Protagonist Therapeutics. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Protagonist Therapeutics and Petros Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Protagonist Therapeutics | N/A | 39.06% | 35.19% |
| Petros Pharmaceuticals | N/A | -95.40% | -27.43% |
Summary
Protagonist Therapeutics beats Petros Pharmaceuticals on 11 of the 14 factors compared between the two stocks.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
About Petros Pharmaceuticals
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
